Q2 2020 Illumina Inc Earnings Call

We are we are I got a PDUFA of the first of February 2020.

Uhhuh.

2021, I'm, sorry, 2021, and a and we will we havent our label today and clinical section of our label the treatment of off episodes and the clinical data. That's there to go with disconnect I think it will allow us to be able to ensure that we enjoy we have m. ours that are appropriately.

Mentioning the indication statement with that fully addresses the full spectrum of motor complications, so we'll double down but it won't change what we're doing I think the messaging around the product. The fact that go covering is approved and the only product that's out there to treat disconnect and off in terms of it.

Clinical benefit.

We'll remain.

Okay, great. Thank you.

We have no further questions at this time ill now turn the call back over to Mr. Neal Mcerlean for closing remarks.

Thank you Gabrall in summary.

We remain focused on our long term goals and continue to execute our growth strategy for discovery.

We've been able to quickly adapt and implement new ways of working for the benefit of patients.

And we believe we have both the people and the resources to execute our near term strategy to deliver value to patients and shareholders I want to thank everybody for joining the call and appreciate your time, we look forward to speaking with you again next quarter. Thank you.

Okay.

This concludes today's conference call you may now disconnect.

[music].